These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15565258)

  • 21. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006.
    Derache A; Maiga AI; Traore O; Akonde A; Cisse M; Jarrousse B; Koita V; Diarra B; Carcelain G; Barin F; Pizzocolo C; Pizarro L; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Sep; 62(3):456-63. PubMed ID: 18556706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia.
    Tee KK; Kamarulzaman A; Ng KP
    Med Microbiol Immunol; 2006 Jun; 195(2):107-12. PubMed ID: 16404607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia.
    Mohamad S; Deris ZZ; Yusoff NK; Ariffin TA; Shueb RH
    Braz J Infect Dis; 2012; 16(3):284-8. PubMed ID: 22729198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.
    Simon V; Vanderhoeven J; Hurley A; Ramratnam B; Louie M; Dawson K; Parkin N; Boden D; Markowitz M
    AIDS; 2002 Jul; 16(11):1511-9. PubMed ID: 12131189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.
    Ruelle J; Roman F; Vandenbroucke AT; Lambert C; Fransen K; Echahidi F; Piérard D; Verhofstede C; Van Laethem K; Delforge ML; Vaira D; Schmit JC; Goubau P
    BMC Infect Dis; 2008 Feb; 8():21. PubMed ID: 18304321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
    Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
    HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: preliminary results.
    Rodrigues R; Vazquez CM; Colares JK; Custodio RM; Bonásser Filho F; Souza Ldo R; Gianna MC; Marques CC; Brígido LF
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):97-102. PubMed ID: 15867972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Resistance to anti-retroviral therapy in Chilean patients with HIV-1 from 2002 to 2005].
    Afani S A; Orellana R L; Duarte J P; Acevedo M W; Morales B O; Wolff R M; Vásquez P; Beltrán C
    Rev Med Chil; 2007 Oct; 135(10):1237-44. PubMed ID: 18180829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
    Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE
    AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
    Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients.
    Doualla-Bell F; Gaseitsiwe S; Ndungú T; Modukanele M; Peter T; Novitsky V; Ndwapi N; Tendani G; Avalos A; Wester W; Bussmann H; Cardiello P; Marlink R; Moffat H; Thior I; Wainberg MA; Essex M
    Antivir Chem Chemother; 2004 Jul; 15(4):189-200. PubMed ID: 15457680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
    van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
    J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential evolution of Human Immunodeficiency Virus type 1 Protease and Reverse Transcriptase genes between HAART-failing and naïve-treated individuals.
    Varella RB; Schrago CG; Zalis MG
    Curr HIV Res; 2009 Nov; 7(6):601-5. PubMed ID: 19929796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran.
    Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.